🔴 Immunitybio is trading 4.1% down today, underperforming a bullish biotech sector

Immunitybio is trading at $6.71 (down 4.1%), underperforming a biotech sector that is currently up over 2% on M&A-driven optimism.

• The move lacks a clearly identified catalyst, with no fresh company-specific headlines, earnings, or FDA updates reported for July 28, 2026.
• Price action appears tied to stock-specific selling and recent volatility, contrasting with the broader sector's upward momentum.